Coherus Oncology Inc. share price logo

Coherus Oncology Inc.

NASDAQ: CHRS

Small Cap

$1.45

-0.05

(-3.67%)

Live

as on

Coherus Oncology Inc. Stock Performance

as on June 30, 2026 at 6:10 am IST

  • Day's Low

    Day's High

    $1.43
    $1.52
    downward going graph

    1.38%

    Downside

    4.83%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.72
    $2.62
    downward going graph

    50.34%

    Downside

    80.40%

    Upside

    downward going graph

Coherus Oncology Inc. share price movements today

Previous Close
$1.50
Open
$1.52
Volume
1.2M
Day's Low - High
$1.43 - $1.52
52 Week Low - High
$0.72 - $2.62

Coherus Oncology Inc. Historical Returns

1 Month Return
-5.66 %
3 Month Return
-7.98 %
1 Year Return
+ 101.86 %
3 Year Return
-64.2 %
5 Year Return
-89.32 %

Coherus Oncology Inc. Stock Fundamentals & Key Indicators

Check Coherus Oncology Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$228.3M

EPS (TTM)

-0.745

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.76%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-163.4M

Revenue (TTM)

46.9M

Profit Margin

397.30%

Return On Equity TTM

33.11%

Coherus Oncology Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Coherus Oncology Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Coherus Oncology Inc. image
Coherus Oncology Inc.
BUY$228.3M-89.32%NA397.30%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$38.7B470.07%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$38.9B75.66%73.0312.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$124.7B149.69%29.1635.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$66.4B15.92%15.4629.65%0.58%

Stock Returns calculator for Coherus Oncology Inc. Stock including INR - Dollar returns

The Coherus Oncology Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Coherus Oncology Inc. investment value today

Current value as on today

₹2,16,158

Returns

₹1,16,158

(+116.16%)

Returns from Coherus Oncology Inc. Stock

₹95,946 (+95.95%)

Dollar Impact

₹20,212 (+20.21%)

Analyst Recommendation on Coherus Oncology Inc. Stock

Based on 16 analysts

BUY

81.25%

Buy

18.75%

Hold

0.00%

Sell

Based on 16 analysts, 81.25% of analysts recommend a 'BUY' rating for Coherus Oncology Inc.. Average target price of $7.8

Coherus Oncology Inc. Share Price Target

Get share price movements and forecasts by analysts on Coherus Oncology Inc..

What analysts predicted

81.41%UPSIDE

Target Price

$7.8

Current Price

$1.45

Analyzed by

16 Analysts

Target

$7.80

Coherus Oncology Inc. target price $7.8, a slight upside of 81.41% compared to current price of $1.45. According to 16 analysts rating.

Indian Investors' Interest in Coherus Oncology Inc. Stock

Search interest for Coherus Oncology Inc. Stock has decreased by -35% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-35% versus previous 30 day period

Coherus Oncology Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
91
2
64
70
54
7
10
11
12
12
Gross Profit
6
0
35
50
20
3
5
6
7
7
Operating Income
-68
-67
-20
-6
-42
-45
-45
-42
-45
-36
EBITDA
-67
-63
-6
-3
-44
-44
-41
-41
-43
-33
Interest Expense
10
11
5
5
5
2
2
2
2
2
Depreciation
1
1
1
1
1
1
1
0
0
0
Income Before Tax
-79
-68
-12
-10
-50
-47
-44
-44
-46
-36
Income Tax Expense
-10
1
-
-
-50
9
-342
-8
-8
1
Net Income
-79
102
-12
-10
-50
-56
-41
-35
-37
-37
Net Profit Margin
-87.03%
4457.32%
-19.88%
-15.19%
-93.63%
-744.43%
-403.11%
-303.42%
-292.42%
-308.20%

Coherus Oncology Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
190
1
1
356
475
326
211
257
266
42
Gross Profit
-64
-158
-1
338
438
268
140
98
149
24
Operating Income
-115
-232
-204
107
156
-263
-256
-203
-111
-179
EBITDA
-116
-225
-204
111
161
-260
-255
-193
60
-170
Interest Expense
7
9
9
17
21
22
32
40
27
9
Depreciation
-
3
3
3
2
3
3
3
5
3
Income Before Tax
-127
-238
-209
92
135
-287
-291
-238
28
-183
Income Tax Expense
0
9
4
2
3
19
34
0
28
-332
Net Income
-127
-238
-209
89
132
-287
-291
-237
28
-170
Net Profit Margin
-66.98%
-15306.56%
-13453.66%
25.23%
27.79%
-87.92%
-138.24%
-92.48%
10.68%
-403.80%

Coherus Oncology Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
102
-54
-10
-50
-56
297
-35
241
-37
Operating Cash Flow
-46
59
-62
28
-25
-46
-46
-19
-57
Investing Cash Flow
202
27
0
0
-17
462
-67
-2
30
Financing Cash Flow
0
-187
0
0
0
-281
0
8
53
Change in Cash
156
-100
-61
28
-43
134
-113
-14
26

Coherus Oncology Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-238
-209
89
132
-287
-291
-237
28
168
Operating Cash Flow
-200
-159
28
154
-37
-241
-174
-20
-138
Investing Cash Flow
-4
-1
-12
-14
-138
-166
144
230
375
Financing Cash Flow
206
105
89
223
51
54
69
-186
-273
Change in Cash
1
-54
104
363
-123
-353
39
22
-37

Global Institutional Holdings in Coherus Oncology Inc.

Funds
Holdings
BlackRock Inc
6.72%
Vanguard Group Inc
6.5%
Millennium Management LLC
0.43%
The Goldman Sachs Group Inc
0.45%
Kohlberg Kravis Roberts & Co LP
1.97%
See all

Insights on Coherus Oncology Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, CHRS stock has moved up by 101.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 594.4% return, outperforming this stock by 658.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 393.3% return, outperforming this stock by 291.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 12.74M → 12.31M (in $), with an average decrease of 3.4% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -35.10M → -37.93M (in $), with an average decrease of 4.0% per quarter

About Coherus Oncology Inc.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
OrganisationCoherus Oncology Inc.
Headquarters333 Twin Dolphin Drive, Redwood City, CA, United States, 94065
IndustryBiotechnology
CEOMr. Dennis M. Lanfear
E-voting on sharesClick here to vote

Key Management of Coherus Oncology Inc.

Name

Title

Mr. Michael Chen

Senior Vice President of Commercial Analytics & Trade

Dr. Theresa M. Lavallee Ph.D.

Chief Development Officer & Chairman of Scientific Advisory Board

Mr. Arvind Sood

Chief Strategy & Corporate Affairs Officer

Ms. Carrie Graham

Vice President of Investor Relations & Advocacy

Mr. Bryan J. McMichael

Chief Financial Officer

Mr. Andy Rittenberg

Chief Legal Officer

Ms. Rebecca Sunshine

Chief Human Resources Officer

Dr. Rosh Dias M.D., MRCP

Chief Medical Officer

Mr. Sameer Goregaoker

Chief Commercial Officer

Mr. Dennis M. Lanfear

Chairman, President & CEO

FAQs

What is Coherus Oncology Inc. share price today?

Coherus Oncology Inc. share price today is $1.45 as on . Coherus Oncology Inc. share today touched a day high of $1.52 and a low of $1.43.

What is the 52 week high and 52 week low for Coherus Oncology Inc. share?

Coherus Oncology Inc. share touched a 52 week high of $2.62 on and a 52 week low of $0.72 on . Coherus Oncology Inc. stock price today i.e. is trending at $1.45,which is 44.57% down from its 52 week high and 101.39% up from its 52 week low.

What is Coherus Oncology Inc.'s market capitalisation today?

Coherus Oncology Inc. market capitalisation is $0.00T as on .

How to invest in Coherus Oncology Inc. Stock (CHRS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Coherus Oncology Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Coherus Oncology Inc. Shares that will get you 1.0345 shares as per Coherus Oncology Inc. share price of $1.45 per share as on June 30, 2026 at 12:40 am IST.

What is the minimum amount required to buy Coherus Oncology Inc. Stock (CHRS) from India?

Indian investors can start investing in Coherus Oncology Inc. (CHRS) shares with as little as ₹94.54 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹945.40 in Coherus Oncology Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Coherus Oncology Inc. share’s latest price of $1.45 as on June 30, 2026 at 12:40 am IST, you will get 6.8966 shares of Coherus Oncology Inc.. Learn more about fractional shares .

What are the returns that Coherus Oncology Inc. has given to Indian investors in the last 5 years?

Coherus Oncology Inc. stock has given -89.32% share price returns and 27% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?